visibility into cell health
Without sampling and without blind spots.
LarmorBio is transforming bioprocessing and biomanufacturing with BioScan-NMR™—the industry’s first continuous, non-invasive, real-time process analytical technology (PAT) platform.
⌄
THE PROBLEM
THE INVISIBLE MANUFACTURING CRISIS
Biologics are made in living cells.
Nobody can see them while they work.
The global biologics industry is worth over $450 billion and growing. The therapies it produces—monoclonal antibodies, cell therapies, gene therapies, vaccines—are among the most valuable and complex medicines ever made.
And yet, at the center of those manufacturing runs sits a blind spot.
Leading to daily windows in which cell state can drift silently toward failure.
When it does, the consequences are severe.
$1M-$2M Lost
The cost of a single failed commercial biologics batch
In cell and gene therapy, the stakes are compounded. The potency assay that certifies whether a cell therapy is ready for a patient takes up to 21 days to complete — and it destroys the very cells it tests. For an autologous therapy, that is not just a quality control problem, it means another patient waiting to be treated.
Today, the only way to know what is happening inside a bioreactor is to open it, draw a sample, send it to a lab, and wait. That process takes hours. It breaks sterility. It consumes scarce product. And it happens, at best, once per shift.
8-12 Hours Offline
The blind spot between offline samples—once per shift, every shift
>7.5% Failures
The failure rate of all industry-wide bioprocessing batches
The industry has invested billions in hardware, automation, and analytics.
But the fundamental visibility problem remains unsolved.
Until now.
THE SOLUTION
BIoscan-nmr™
Continuous. Non-invasive. Real-time.
BioScan-NMR reads the magnetic resonance signal of water through the wall of an existing circulating line — no sampling, no reagents, no sterility breach, no change to the bioreactor.
A plug-and-play sensor sleeve wraps around a line the process already has. Advanced analytics translate the signal into actionable process intelligence, updated every two minutes, around the clock.
Zero Samples
Reads through the tubing wall, leaving the product path completely closed
Plug-and-Play
A sleeve on an existing circulating line, no bioreactor modification is needed
GMP-Ready
Designed for the regulated manufacturing environment from day 1; deployable in hours
BioScan-NMR is built around the way a CDMO actually runs — a sleeve on a line that already exists, no new sterility interface, no change to the client's process. It is the continuous, non-invasive monitoring capability you can offer on a client's batch that your competitors cannot.
validated.
Bioscan-NMR tracks cell density continuously and accurately, without a single sample.
Provides quantitative readouts that match state-of-the-art offline assays.
SUPERIOR.
Bioscan-NMR’s continuous, non-invasive measurement gives manufacturers gold-standard insights sooner.
CDMOs can catch failing batches earlier.
MIT-SPINOUT ESTABLISHED IN 2021
Founded on breakthrough technology developed at MIT's Research Laboratory of Electronics and Singapore MIT Alliance for Research and Technology.
VALIDATED IN 19 PEER-REVIEWED PUBLICATIONS
19 peer-reviewed publications validating LarmorBio’s importance in clinical diagnostics and life science research.
pressure-tested with >5,000 patients
Currently used in studies worldwide, representing thousands of patients in major disease areas impacting human health.
PROTECTED WITH 7 FILED PATENTS
The intellectual property portfolio includes 2 issued and 5 pending patents focused on microscale magnetic resonance technology for measuring oxidative stress in blood and for life sciences applications.
Meet the team
-
![]()
Rodolfo Rohr
CEO/FOUNDER
With a vision for building something meaningful, our founder brings a blend of big-picture thinking and hands-on experience. Engineer-entrepreneur; successful exit from a prior medical-robotics company, Interactive Motion Technologies. -
![]()
Louis Bouchard, Ph.D.
CSO
20+ years developing magnetic resonance for biological applications, including at UCLA. -
![]()
Jongyoon Han, Ph.D.
INVENTOR
MIT Professor of Biological & Electrical Engineering; inventor of the MRR platform. -
![]()
Yie Hou Lee
SCIENTIFIC ADVISOR
Biomarker R&D executive, from discovery to clinical translation at the Singapore-MIT Alliance for Research and Technology (SMART).
board of directors
-
![]()
Emory Anderson
BOARD MEMBER
Executive & board leader; former CEO of a leading medical diagnostics company
-
![]()
Glenn Snyder
BOARD MEMBER
Led Deloitte’s medtech consulting practice as part of his 30 years in healthcare.
